AU9537098A - 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein - Google Patents

4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Info

Publication number
AU9537098A
AU9537098A AU95370/98A AU9537098A AU9537098A AU 9537098 A AU9537098 A AU 9537098A AU 95370/98 A AU95370/98 A AU 95370/98A AU 9537098 A AU9537098 A AU 9537098A AU 9537098 A AU9537098 A AU 9537098A
Authority
AU
Australia
Prior art keywords
phenyltetrahydrochinoline
inhibitor
utilized
transfer protein
cholesterol ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU95370/98A
Other languages
English (en)
Inventor
Hilmar Bischoff
Arndt Brandes
Klaus-Dieter Bremm
Michael Logers
Carsten Schmeck
Delf Schmidt
Gunter Schmidt
Jurgen Stoltefuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU9537098A publication Critical patent/AU9537098A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AU95370/98A 1997-09-19 1998-09-07 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein Abandoned AU9537098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19741399 1997-09-19
DE19741399A DE19741399A1 (de) 1997-09-19 1997-09-19 Tetrahydrochinoline
PCT/EP1998/005658 WO1999015504A1 (de) 1997-09-19 1998-09-07 4-phenyltetrahydrochinoline als hemmer des cholesterolestertransferproteins

Publications (1)

Publication Number Publication Date
AU9537098A true AU9537098A (en) 1999-04-12

Family

ID=7842954

Family Applications (1)

Application Number Title Priority Date Filing Date
AU95370/98A Abandoned AU9537098A (en) 1997-09-19 1998-09-07 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Country Status (6)

Country Link
US (4) US6291477B1 (https=)
EP (1) EP1017677A1 (https=)
JP (1) JP2001517655A (https=)
AU (1) AU9537098A (https=)
DE (1) DE19741399A1 (https=)
WO (1) WO1999015504A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
JPH11185506A (ja) * 1997-12-24 1999-07-09 Koito Mfg Co Ltd 車輌用前照灯
DE69925612T2 (de) * 1998-09-25 2006-03-16 Monsanto Co., Chicago (r)-chirale halogenierte 1-substituierte amino-(n+1)-alkanolen für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
EE200400034A (et) 2001-06-22 2004-06-15 Pfizer Products Inc. Amorfse ravimaine adsorbaatide farmatseutilised kompositsioonid
DE10148436A1 (de) * 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
WO2006065842A2 (en) * 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
WO2006063828A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
DE102006012548A1 (de) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AU2011274903B2 (en) 2010-07-09 2016-09-08 Daiichi Sankyo Company, Limited Substituted pyridine compound
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
ES2599757T3 (es) 2012-01-06 2017-02-03 Daiichi Sankyo Company, Limited Sales de aducto de ácido de un compuesto de piridina sustituido como inhibidores de la proteína de transferencia de ésteres de colesterilo (PTEC)
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
CN104583197B (zh) * 2012-08-24 2017-05-17 霍夫曼-拉罗奇有限公司 新型双环吡啶衍生物
DE102013223272A1 (de) * 2013-11-14 2015-05-21 Bombardier Transportation Gmbh Verfahren zur Herstellung eines rohrförmigen Ausstattungselements für ein Schienenfahrzeug
CN117427074A (zh) * 2023-11-13 2024-01-23 山东第一医科大学(山东省医学科学院) 四氢喹啉醇作为铁死亡抑制剂在制备急性肾损伤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
NZ237097A (en) 1990-02-26 1993-12-23 Squibb & Sons Inc Pyridine derivatives substituted in the 3-position by a phosphinic moiety.
DE19627419A1 (de) 1996-07-08 1998-01-15 Bayer Ag Cycloalkano-pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19707199A1 (de) 1997-02-24 1998-08-27 Bayer Ag Neues Verfahren zur Herstellung von Cycloalkanopyridinen
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline

Also Published As

Publication number Publication date
US20030232990A1 (en) 2003-12-18
US6562976B2 (en) 2003-05-13
JP2001517655A (ja) 2001-10-09
US6291477B1 (en) 2001-09-18
WO1999015504A1 (de) 1999-04-01
US20020042515A1 (en) 2002-04-11
US20020165252A1 (en) 2002-11-07
US6897317B2 (en) 2005-05-24
DE19741399A1 (de) 1999-03-25
EP1017677A1 (de) 2000-07-12

Similar Documents

Publication Publication Date Title
AU9537098A (en) 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein
AU6724598A (en) 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors
AU6482398A (en) Sulfonylaminocarboxylic acids
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU8289298A (en) Phosphocholines of retinoids
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
AU3140695A (en) 1h-indole-1-functional spla2 inhibitors
AU8740398A (en) Amplification of nucleic acids
AU6490396A (en) Substituted-pent-4-ynoic acids
AUPN741696A0 (en) Delivery of nucleic acids ii
AU6882598A (en) Protein kinase inhibitor
AU6161099A (en) Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
AU2646497A (en) Amplification of nucleic acids
AU1605699A (en) Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (ii)
AU6760798A (en) Bax inhibitor proteins
AU3120297A (en) Human phospholipase inhibitor
AU8289498A (en) Novel polyamphoteric phosphate ester surfactants
AU9443898A (en) Wof inhibitor
AU8673598A (en) Neuraminidase inhibitors
AUPP076797A0 (en) Phospholipase inhibitor
AU6422798A (en) Stabilized urease inhibitor
AU2545697A (en) Novel uses of phospholipase c inhibitors
AU3061499A (en) Aryl- and heteroarylamides of carboalkoxysulfanilic acids
AU6516998A (en) Lipid a1-position carboxylic acid derivatives
AU6516296A (en) Novel quinoxaline- and quinoxalinylalkane-phosphonic acids

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase